- Pfizer PFE announced positive top-line results from a pivotal Phase 3 study evaluating the safety, tolerability and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy subjects 10 to 25 years of age. The study met all primary and secondary endpoints. Pfizer shares traded in a daily volume of 15.14 million shares in a range of $45.7 to $46.29 to close the regular trading session at $45.94.
- Alnylam (NASDAQ:ALNY) and Regeneron (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 for the treatment of nonalcoholic steatohepatitis (NASH). Alnylam shares traded in a range of $202.6-$210.86 on daily volume of 771.5 thousand shares and closed the regular trading session at $208.48.
- The US Food and Drug Administration (FDA) has granted orphan drug status Kymera Therapeutics‘ CYMR Product candidate KT-333 for the treatment of cutaneous T-cell lymphoma (CTCL). Kymera shares traded up 6.33 percent in a range of $27.41 to $29.57 on daily volume of 581.28 thousand shares and closed the regular trading session at $28.76.
- Jasper therapeutics JSPR announced that its lead compound JSP191 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with severe combined immunodeficiency syndrome (SCID) undergoing allogeneic hematopoietic stem cell transplantation. Jasper shares traded up 22.56 percent, ranging from $1.27 to $1.63 on daily volume of 395.73 thousand shares versus a three-month moving average of 47.29 thousand shares, the regular Trading session closed at $1.30.
- The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion Candel Therapeutics‘ CADL Application for orphan drug status for CAN-2409 for the treatment of glioma. Candel shares traded up 3.99 percent in a range of $3.34 to $3.65.
